Takeda Pharmaceutical (TAK) Change in Receivables (2018 - 2026)

Takeda Pharmaceutical's Change in Receivables history runs 9 years deep, the most recent figure standing at -$621.8 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 584.76% year-over-year to -$621.8 million; the TTM figure through Mar 2026 stood at -$427.1 million (down 11.97% YoY), while the FY2026 annual figure was -$466.1 million, down 20.43% from the prior year.
• Change in Receivables was -$621.8 million for Q1 2026 at Takeda Pharmaceutical, down from -$71.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $516.1 million in Q1 2023 to a low of -$659.4 million in Q2 2023.
• Historically, Change in Receivables has averaged $11.2 million across 5 years, with a median of $83.4 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables surged 208.35% in 2025, then sank 584.76% in 2026.
• A 5-year view of Change in Receivables shows it stood at $90.4 million in 2022, then gained by 6.93% to $96.7 million in 2023, then declined by 13.75% to $83.4 million in 2024, then tumbled by 185.24% to -$71.1 million in 2025, then slumped by 775.04% to -$621.8 million in 2026.
• The last three Change in Receivables figures came in at -$621.8 million (Q1 2026), -$71.1 million (Q4 2025), and -$66.5 million (Q3 2025), per Business Quant data.